An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Apellis Pharmaceuticals, Inc.98 个研究点分布在 17 个国家目标入组 160 人2018年8月27日

适应症PNH

干预措施Pegcetacoplan

概览

阶段: 3 期
干预措施: Pegcetacoplan
疾病 / 适应症: PNH
发起方: Apellis Pharmaceuticals, Inc.
入组人数: 160
试验地点: 98
主要终点: Incidence and severity of treatment-emergent adverse events
状态: 进行中（未招募）
最后更新: 26天前

概览研究者入排标准研究组 & 干预措施结局指标研究点相似试验

概览

简要总结

This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.

注册库

clinicaltrials.gov

开始日期

2018年8月27日

结束日期

2026年7月1日

最后更新

26天前

研究类型

Interventional

研究设计

Single Group

性别

All

研究者

发起方

Apellis Pharmaceuticals, Inc.

责任方

Sponsor

入排标准

入选标准

•Subjects at least 18 years of age with PNH who have participated in a pegcetacoplan clinical trial. Subjects who received treatment with pegcetacoplan must have experienced clinical benefit and adequate tolerability in the opinion of the investigator.
•Note: Subjects with PNH who completed a pegcetacoplan clinical trial without receiving pegcetacoplan (or without receiving pegcetacoplan for long enough to demonstrate clinical benefit) may be enrolled in this study if, in the opinion of the Investigator, the subject is expected to demonstrate clinical benefit upon the initiation or continuation of pegcetacoplan therapy.
•Vaccination against Neisseria meningitidis types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day 1 dosing of this study, or within 14 days after starting treatment with pegcetacoplan. Vaccination is mandatory unless documented evidence exists that subjects are nonresponders to vaccination as evidenced by titers or display titer levels within acceptable local limits. Immunization status checks will be performed to determine whether subjects require primary or booster vaccinations.
•Willing and able to give written informed consent.
•Willing and able to self-administer pegcetacoplan (administration by caregiver will be allowed)
•Women of childbearing potential (WOCBP) defined as any females who have experienced menarche and who are NOT permanently sterile or postmenopausal must have a negative pregnancy test and must agree to continue to use an approved method of contraception for the duration of the study and 90 days after their last dose of study drug. Note: Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.
•Males must agree to continue to use an approved method of contraception and must agree to refrain from donating sperm for the duration of the study and 90 days after their last dose of study drug.

排除标准

•Subjects who have withdrawn from a pegcetacoplan clinical study.
•Any condition that could increase the subject's risk by participating in the study.
•Any comorbidity or condition (such as malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound study data.
•History or presence of hypersensitivity or idiosyncratic reaction to compounds related to the investigational product or SC administration.
•Known infection with hepatitis B, C, or HIV.
•Hereditary complement deficiency.
•History of bone marrow transplant.
•Concurrent severe aplastic anemia (SAA), defined as currently receiving immunosuppressive therapy for SAA including but not limited to cyclosporin A, tacrolimus, mycophenolate mofetil or anti-thymocyte globulin.
•History of meningococcal disease.
•Concomitant treatment with any complement inhibitor (eg, eculizumab, ravulizumab).